Microsure
Microsure develops robot-assisted microsurgical systems (MUSA-3) that filter physiological tremor and scale hand movements, enabling surgeons to perform supermicrosurgery on sub-millimeter structures such as lymphatic ducts, blood vessels, and nerves at hospitals and academic medical centers.
- Company typePrivate
- Founded2016
- HeadquartersSon En Breugel, Netherlands
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Microsure does
Microsure is a Netherlands-based medical robotics company developing robot-assisted systems for open microsurgery and supermicrosurgery. Founded in 2016 and headquartered at Science Park Eindhoven in Son en Breugel, within the Brainport Eindhoven medtech cluster, the company builds the MUSA platform — a surgeon console paired with a robotic arm cart that uses disposable instrument adapters to allow surgeons to operate with their own familiar microsurgical instruments (forceps, needle holders, scissors). The system applies software-based motion scaling (approximately 4× to 7×) and tremor filtration (attenuating 7–12 Hz physiological tremor at ~50 μm amplitude) to joystick inputs, enabling procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The current flagship product is MUSA-3 (CE-marked May 2026, FDA clearance in progress), which builds on the clinical experience of its predecessor MUSA-2 (the world's first CE-certified microsurgical robot, launched 2019, now out of production).
The company has accumulated clinical evidence across approximately 50 patients at European academic medical centers including Maastricht UMC+ and Uppsala University Hospital, with studies spanning lymphatic surgery, free flap surgery, and peripheral nerve repair. Microsure has assembled a Medical Advisory Board of globally recognized microsurgeons (including Prof. Peter Neligan at University of Washington and Dr. Jesse Selber at Corewell Health) and integrated its platform with the Olympus OrbEye 3D 4K digital exoscope for heads-up microsurgery. The technology stack is sensor-based motion processing rather than learning-based AI; the differentiator is purpose-built engineering for open microsurgery rather than adaptation from laparoscopic systems.
Microsure generates revenue primarily through capital sales of the MUSA-3 system to hospitals and academic medical centers, supplemented by service and support, with a recently added leasing channel through kineo for capital-light hospital adoption. The go-to-market is enterprise field sales targeting leading European centers for clinical evidence generation and KOL adoption ahead of broader commercialization, supported by conference presence (EFSM, EURAPS, EPSRC, RAMSES, WSRM), peer-reviewed publications, and a Medical Advisory Board strategy. Ownership is venture-backed and private, with investors including Innovation Industries, EIC Fund, Invest-NL, kineo, BOM Ventures, TCIM, Venturing Tech, Eindhoven University of Technology, and the Dutch Ministry of Economic Affairs; the company has raised approximately €40M cumulatively and appointed Michel Therin (ex-Medtronic, ex-Siemens Healthineers) as Supervisory Board Chair in September 2025 ahead of its commercial phase.
Microsure firmographics
Firmographics- Name
- Microsure
- Legal name
- Microsure BV
- Website
- https://microsure.nl
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Microsure develops robot-assisted microsurgical systems (MUSA-3) that filter physiological tremor and scale hand movements, enabling surgeons to perform supermicrosurgery on sub-millimeter structures such as lymphatic ducts, blood vessels, and nerves at hospitals and academic medical centers.
- Ownership category
- akta.pro rank
Microsure industry classification
Industry- Product category
- Surgical Robotics
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
- akta.pro secondary industry
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
Keywords
Where Microsure is headquartered
LocationHeadquarters
- HQ city
- Son En Breugel
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
Microsure business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- MUSA-3 Surgical Robot Sales: Microsure generates revenue through the sale of its MUSA-3 microsurgical robot system to hospitals and medical centers. The company has entered into asset financing agreements with kineo to offer leasing options to hospitals adopting MUSA-3.
- Service and Support: Ongoing service, support, and potentially consumables associated with the MUSA-3 system and clinical partnerships.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
Microsure product offering
Product offeringCore offering
Microsure develops and sells robot-assisted microsurgical systems, primarily the MUSA-3 platform, which enables surgeons to perform super-microsurgical procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The system consists of a surgeon console with joysticks and a robotic arm cart, using disposable adapters that allow surgeons to operate with their own familiar microsurgical instruments. MUSA-3 applies motion scaling (~4x to 7x reduction) and software-based tremor filtration to deliver consistent precision for procedures such as lymphatic surgery, free flap surgery, and peripheral nerve repair.
Product overview
Microsure offers a portfolio of dedicated microsurgical robots centered on its MUSA platform. The current flagship product is MUSA-3, a third-generation robotic system for supermicrosurgery that consists of a surgeon console and robotic arm cart, using disposable adapters to enable surgeons to use their own trusted instruments. The earlier MUSA-2 (launched 2019) was the world's first CE-certified microsurgical robot and served as the clinical prototype for validating the technology; it is no longer in production. MUSA-3 builds on MUSA-2 with enhanced dexterity, wider workspace, improved tremor reduction, and regulatory approval (CE mark obtained May 2026).
Differentiator
Problem solved
Functional benefit
Brands
- MUSA-3: Third-generation microsurgical robot with enhanced dexterity, tremor filtration, motion scaling, and ergonomic surgeon console for supermicrosurgery procedures.
- MUSA-2
Products and services
- MUSA-3 Third-generation microsurgical robot designed to assist surgeons during open super-microsurgical procedures by downscaling and stabilizing hand movements. Consists of a surgeon console with joysticks and a robotic arm cart using disposable adapters that allow surgeons to work with their own trusted microsurgical instruments. Features motion scaling (~4x and 7x), tremor filtration, ergonomic seated operation, and compatibility with digital or hybrid microscopes. CE marked (May 2026); intended for hospital microsurgery departments and reconstructive surgery centers.
Quantifiable outcome
- Surgeons using MUSA achieved consistent anastomoses of 0.3mm vessels, a task extremely difficult by hand
- +2 more outcomes
Companies that use Microsure
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles2 records
Microsure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature5 records
Microsure partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Maastricht UMC+coreKey clinical partner conducting clinical studies with MUSA-2 and MUSA-3 systems for lymphatic surgery, free flap surgery, and peripheral nerve repair. Dr. Tom van Mulken from Maastricht UMC+ earned his PhD on advancements in robotic microsurgery.
- Uppsala Academic HospitalcoreClinical partner in Sweden conducting clinical studies and in-vitro research. Dr. Maria Mani from Uppsala University Hospital serves on Microsure's Medical Advisory Board.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Microsure competitors and assessment
Company assessmentDirect peers
- Medical Microinstruments (MMI): MMI develops the Symani surgical robot, the most direct competitor to MUSA-3 in microsurgical and supermicrosurgical robotics. Both target lymphatic, free flap, and peripheral nerve procedures with motion scaling and tremor filtration, competing for the same European academic reference centers.
Broad incumbents
- Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics incumbent with the da Vinci platform. It is not specialized in open microsurgery but sets the benchmark for hospital capital robotics purchasing decisions and represents the most significant long-term competitive threat as it expands indications.
- Stryker: Stryker is a broad medical device incumbent with the Mako robotics platform in orthopedics and a growing surgical technologies portfolio. As a large, well-capitalized player adjacent to surgical robotics, it could extend into microsurgical indications.
- Medtronic: Medtronic's Hugo robotic-assisted surgery platform competes in general soft-tissue surgery and the company has deep hospital relationships across Europe. Its scale and balance sheet make it a credible potential entrant into adjacent microsurgical applications.
- Johnson & Johnson (Ethicon / Auris Health): J&J's Ottava general surgery robotics platform (Ethicon) and the MONARCH bronchoscopy platform (Auris Health) make it a broad surgical robotics incumbent with the resources to compete in multiple specialty surgical categories over time.
Emerging players
- CMR Surgical: CMR Surgical's Versius system is a portable, modular laparoscopic surgical robot that competes for hospital capital budgets in Europe. While not microsurgery-focused, it shares Microsure's enterprise sales motion and European hospital customer base.
- Moon Surgical: Moon Surgical (with the Maestro system) is an emerging surgical robotics company backed by major medtech investors, focused on the laparoscopic operating room. It is comparable in stage, capital intensity, and enterprise sales model rather than in clinical indication.
- Asensus Surgical: Asensus Surgical (formerly TransEnterix) develops the Senhance surgical robotics platform with digital surgery features. It is an emerging surgical robotics competitor pursuing hospital accounts with a similar enterprise sales motion to Microsure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Microsure social profiles
Digital presenceMicrosure compliance and trust
Trust signalCompliance3 records
Microsure financial estimates
Financial estimateRevenue estimate
Valuation estimate
Microsure leadership team
Management profileNumber of profiles
Profiles5 records
Microsure funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Microsure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Microsure
What does Microsure do?
Microsure develops and sells robot-assisted microsurgical systems, primarily the MUSA-3 platform, which enables surgeons to perform super-microsurgical procedures on sub-millimeter anatomical structures such as lymphatic ducts, blood vessels, and nerves. The system consists of a surgeon console with joysticks and a robotic arm cart, using disposable adapters that allow surgeons to operate with their own familiar microsurgical instruments. MUSA-3 applies motion scaling (~4x to 7x reduction) and software-based tremor filtration to deliver consistent precision for procedures such as lymphatic surgery, free flap surgery, and peripheral nerve repair.
Is Microsure a public or private company?
Microsure is a private company. It is classified as venture growth investor backed and is currently operating.
When was Microsure founded?
Microsure was founded in 2016. It employs 51 to 100 people.
Where is Microsure based?
Microsure is headquartered in Son En Breugel, Netherlands, in the Europe region.
How does Microsure make money?
Two revenue lines are on record. MUSA-3 Surgical Robot Sales are the primary driver. The others are service and Support.
Who are Microsure's main competitors?
Medical Microinstruments (MMI) is listed as a direct peer. Broad incumbents are Intuitive Surgical, Stryker, Medtronic and Johnson & Johnson (Ethicon / Auris Health). Emerging players are CMR Surgical, Moon Surgical and Asensus Surgical.
Does Microsure have an API?
No public API is recorded for Microsure.
What industry is Microsure in?
Microsure's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS). Its NAICS code is 339112 and its SIC code is 3841.